ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)

项目总结 拟议的白血病翻译科学中心(LTSC)将产生、协调和领导翻译 在ECOG-ACRIN和国家临床试验网络(NCTN)内进行的白血病研究。长期合作伙伴关系委员会将 作为白血病实验室委员会(LLC)研究的中心，得到 白血病转化实验室(LTRL)和白血病组织库(LTB)，以及一个全面的 白血病数据仓库。LTSC由R.Levine、A.Melnick和A.Ferrando领导。他们已经发展出 在翻译研究领导和实施最先进的相关技术方面有着广泛的记录 白血病生物学研究。通过与MSK中心的合作，LTSC得到了进一步的加强 分子肿瘤学和恶性血液病中心，提供高通量 基因组学技术，最先进的基因组平台，计算资源，以及 执行广泛的CLIA认证的临床基因组分析。为了最大限度地加速高质量 临床试验基于最重要的科学，LTSC将建立一个互动框架，将 吸引初级和高级临床研究人员、实验室科学家、计算生物学家、生物统计学家 和其他人，并使他们能够组成协同研究团队。长春藤小组委员会将提供试验计划经费，以 跨学科团队以启动这些项目和广泛的科学资源，包括 获得患者样本和临床/分子数据、基因组和表观遗传学分析能力以及 分析平台、科学支持和一个强大的、富有成效的合作白血病研究社区。在……里面 这样，LTSC将确保翻译科学研究无缝地整合到白血病中 临床试验，以确定反应/结果的预测因素，确定和测试新的治疗方法，并开发 评估抗白血病治疗反应的创新性相关研究。通过这些活动， LTSC旨在通过开发和实施 个性化的诊断方法、生物标志物和治疗方法。

PROJECT SUMMARY The proposed Leukemia Translational Science Center (LTSC), will generate, coordinate and lead translational studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the Leukemia Translational Laboratory (LTRL) and the Leukemia Tissue Bank (LTB), and a comprehensive Leukemia Data Warehouse. The LTSC is led by R. Levine, A. Melnick, and A. Ferrando. They have developed an extensive track record in translational research leadership and implementation of state-of-the-art correlative studies in leukemia biology. The LTSC is further enhanced through its partnership with the MSK Centers for Molecular Oncology and Center for Hematologic Malignancies, which provide access to high-throughput genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality clinical trials based on the most important science, the LTSC will establish an interaction framework that will attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including access to patient samples and clinical/molecular data, genomic and epigenetic profiling capabilities and analytic platforms, scientific support, and a robust, productive collaborative leukemia research community. In this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the LTSC aims to transform the standard practice of leukemia care with the development and implementation of personalized diagnostic methods, biomarkers and therapies.